About Us

Mark Iwicki

Chairman and Chief Executive Officer

Mr. Iwicki has 25 years of experience as a pharmaceutical industry leader across multiple therapeutic areas. He has extensive experience building businesses and has been instrumental in the success of a number of drugs, including Prilosec®, Diovan®, Zelnorm®, Lunesta®, and Latuda®. Prior to joining Kala, Mr. Iwicki was President and Chief Executive Officer of Civitas Therapeutics, which was acquired by Acorda Therapeutics.   Read More »


Howard B. Rosen

Board Member

Mr. Rosen brings more than 25 years of experience serving in management and board positions in the biotechnology industry. He currently serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), ALCOBRA, LTD (NASDAQ: ADHD), where he has served as Chairman since 2014, ALDEA Pharmaceuticals, Inc., Entrega, Inc., and PaxVax, Inc., where he has served as Chairman since 2011. From 2010 to 2011, he served as interim President and Chief Executive Officer of Pearl Therapeutics, which was acquired by AstraZeneca in June 2013.  Read More »


Robert Langer, ScD

Co-Founder and Board Member
David H. Koch Institute Professor, MIT

Dr. Langer is an Institute Professor at MIT (there are 11 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). His h-index of 211 is the highest of any engineer in history and he has over 1,080 issued and pending patents worldwide. His patents have been licensed or sublicensed to over 300 companies.  Read More »


Chen Yu, MD, MBA

Board Member
Managing Partner, Vivo Capital

Dr. Yu is a Managing Partner who joined Vivo in 2004. At Vivo, Dr. Yu invests in both private and public pharmaceutical and medical device companies in the US and China. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including Sagent Pharmaceuticals (NASDAQ:SGNT) and China KangHui (NYSE: KH).   Read More »


Gregory Grunberg, MD, MBA

Board Member
Managing Director, Longitude Capital

Dr. Grunberg is a Managing Director at Longitude Capital focused on healthcare investments. Current and prior investments include Kala Pharmaceuticals, California Cryobank, BAROnova, Aquesys (acquired), Practice Fusion, and SARcode (acquired).  Read More »


Kevin Bitterman, PhD

Board Member
Partner, Polaris Partners

Dr. Bitterman is a Partner at Polaris Partners. He joined Polaris in 2004 and focuses on investments in healthcare. Dr. Bitterman is a co-founder of Genocea Biosciences (NASDAQ: GNCA) and Sirtris Pharmaceuticals (NASDAQ:SIRT) (GSK), and was the founding CEO of Editas Medicine and Visterra. He currently represents Polaris as a Director of Editas Medicine, InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical, and Vets First Choice.  Read More »


Rajeev Shah

Board Member
Managing Director & Portfolio Manager, RA Capital

Rajeev Shah is a Managing Director and Portfolio Manager at RA Capital Management. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools.   Read More »


Robert Paull

Board Member
Co-Founder and Venture Partner, Lux Capital

Mr. Paull is Co-Founder and Venture Partner of Lux Capital, focusing on ventures in healthcare. He manages Lux Capital’s investments in Kyruus (healthcare IT), Cala Health (bioelectronics), Cerulean Pharmaceuticals (NASDAQ: CERU - pharmaceutical nanoencapsulation), Magen Biosciences (acquired by PPD - dermatology), Molecular Imprints (acquired by Canon - semiconductor imprint lithography), and Visterra, Inc. (infectious diseases). Mr. Paull was also founding CEO of Genocea Biosciences (NASDAQ: GNCA - vaccine discovery) and founding CEO of Kala Pharmaceuticals.  Read More »


Robert Tepper, MD

Board Member
Partner, Third Rock Ventures

Dr. Tepper is a distinguished scientist with over 30 years of experience building and operating leading R&D operations. He co-founded Third Rock Ventures in 2007 and focuses on the formation, development and scientific strategy of the portfolio companies, as well as actively identifying and evaluating new investments.   Read More »